<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218592</url>
  </required_header>
  <id_info>
    <org_study_id>17-0546</org_study_id>
    <secondary_id>1R01AI122319-01</secondary_id>
    <nct_id>NCT03218592</nct_id>
  </id_info>
  <brief_title>ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence</brief_title>
  <acronym>ENLIGHTEN</acronym>
  <official_title>ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Perform a 3-phase (single dose, multi dose, dose proportionality) study in healthy
      volunteers using daily tenofovir+emtricitabine, dolutegravir, and maraviroc dosing to
      quantify intra- and inter-subject variability and dose proportionality. The influence of
      covariates on ARV hair distribution (e.g., hair growth rate, race, hair color, hair
      treatment) will also be measured. Using both population PK modeling and physiologic based PK
      (PBPK) approaches, a statistical model to quantify ARV adherence patterns based on signal
      intensity/pattern will be developed.

      Participants: Healthy volunteers, aged 18 to 70 years of age, inclusive on the date of
      screening, with an intact gastrointestinal system and at least 1cm caput hair.

      Procedures (methods): Participants will be sequentially assigned to enroll in a dosing arm,
      beginning with maraviroc (MVC), then dolutegravir (DTG), and ending with
      tenofovir/emtricitabine (TFV/FTC). All participants will take a single observed dose of study
      product in Phase 1, with blood and hair samples obtained on Days 3, 7, 14, 21 and 28 days
      post-dose. In Phase 2, all participants take 28 days straight of daily dosing, observed, of
      the same study product. Blood and hair samples obtained on the same days post-dose. In Phase
      3, participants will be randomized to stop their drug, or decrease dosing to one or three
      doses weekly. Hair and blood samples will again be obtained on the same days post-dose. All
      participants will complete a follow-up safety visit with 14 days of completing study
      sampling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Details:

      Participants will be sequentially assigned to enroll in dosing arm, beginning with Maraviroc,
      then Dolutegravir and ending with Tenofovir/Emtricitabine, Participation will last
      approximately 3 months and will include a screening visit, three 28-day phases, and a
      follow-up safety visit.

      Phase 1 consists of a 28-day study period with a single dose of study product on Day 0.

      Phase 2 consists of a 28-day study period with each subject receiving a single daily observed
      dose of study product beginning on Day 0.

      Phase 3 consists of a 28-day study period, with three randomized drug-dosing schemas
      beginning on Day 0. Participants will either: stop taking their study product, dose once per
      week, or dose three times per week.

      Participants will return to the clinic for hair and blood sampling on days 3/7/14/21/28
      post-dose for all three phases. Adverse events will be assessed at every visit. Safety labs
      will be drawn at the midpoint and at the end of each study phase, and at any time indicated
      due to suspected adverse events.

      Description of Study Phases Screening: Participants will be recruited from a variety of
      advertisements, and pre-screened using a telephone Institutional Review Board (IRB)-approved
      questionnaire. If participants are interested and pass the initial screening, a screening
      study visit in the research center will be scheduled. This visit should take approximately 90
      minutes, during which full physical examination and medical history will be obtained, as well
      as physical diagnostics to assess for eligibility. This visit must be completed within the 28
      days prior to enrollment.

      Phase 1: Consists of a 28-day study period, with a single dose of study product on Day 0
      (Maraviroc, Dolutegravir, or tenofovir/emtricitabine). Day 0 can be scheduled on either
      Mondays or Tuesdays, and once eligibility is confirmed on the day of enrollment, a witnessed
      dose of study product will be administered. Participants will return to the clinic for hair
      and blood sampling on Days 3/7/14/21/28 days post-dose. Adverse events will be assessed at
      every visit. Safety labs will be drawn at the midpoint and at the end of the study phase, and
      at any time indicated due to suspected adverse events. These visits should last less than 30
      minutes.

      Phase 2: Consists of a 28-day study period, with each subject receiving a single daily
      observed dose of study product beginning on Day 0. Day 0 can be scheduled on either Mondays
      or Tuesdays, once continued eligibility is confirmed. Target scheduling will have Phase 2
      begin within 2 weeks of completing Phase 1, but could be extended up to 28 days as clinic
      availability dictates. Participants will return to the clinic daily for dosing, and for hair
      and blood sampling on Days 3/7/14/21/28 days post-dose. Adverse events will be assessed at
      every visit. Safety labs will be drawn at the midpoint, and at the end of the study phase,
      and at any time indicated due to adverse events. These visits should last less than 30
      minutes. Dosing only visits should last less than 5 minutes.

      Phase 3: Consists of a 28-day study period, with three randomized drug-dosing schemas. Day 0
      can be scheduled on Mondays, Tuesdays or Fridays, once continued eligibility is confirmed.
      Target scheduling will have Phase 3 begin as soon as possible after completing Phase 2, on a
      Monday/Tuesday/Or Friday within the week. On Day 0, participants will be randomized to one of
      3 potential dosing schemes:

        1. No further doses

        2. One dose weekly (Day 0, 7, 14, 21) 4 doses

        3. Three Doses weekly (Mondays, Wednesdays, Fridays) (Days 0, 2, 4, 7, 9, 11, 14, 16, 18,
           21, 23, 25) 12 doses

      Participants will return to clinic for observed dosing as scheduled, and for hair and blood
      sampling on days 3/7/14/21/28). Safety labs will be drawn at the midpoint, at the end, and at
      any time indicated due to adverse events. These visits should last less than 30 minutes.
      Dosing only visits should last less than five minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">December 7, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective. Single-center, open-label, 3-arm, triple stage study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair Antiretroviral Imaging</measure>
    <time_frame>Up to 28 days post dose</time_frame>
    <description>Signal Strength concentrations will be measured in hair for all study drugs, inclusive of FTC (emtricitabine), tenofovir (TFV), maraviroc (MRV), and dolutegravir (DTG) using Matrix-assisted Laser Desorption Electrospray Ionization (IR-MALDESI) to be reported by signal abundance (au). Signal abundance is the industry standard unit, and higher values represent greater signal with capability to relate to comparative concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Mononuclear Cells (PBMC) Antiretroviral Concentrations</measure>
    <time_frame>Up to 28 days post-dose</time_frame>
    <description>Concentrations of emtricitabine-triphosphate, tenofovir-diphosphate will be measured in peripheral blood mononuclear cells in the Truvada arm only. Truvada is a combination pill, so results for both FTC and TFV are reported in separate columns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Antiretroviral Concentrations</measure>
    <time_frame>Up to 28 days post-dose</time_frame>
    <description>Concentrations will be measured in hair of all study drugs, inclusive of FTC (emtricitabine), TFV (tenofovir), MRV (Maraviroc), and DTG (dolutegravir)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole Blood Antiretroviral Concentrations</measure>
    <time_frame>Up to 28 days post-dose</time_frame>
    <description>Concentrations will be measured in dried blood spots of all study drugs, inclusive of FTC (emtricitabine), TFV (tenofovir), MRV (Maraviroc), and DTG (dolutegravir). Truvada is a combination pill, so results for both FTC and TFV are reported in separate columns.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc Pill</intervention_name>
    <description>Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir Pill</intervention_name>
    <description>Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
    <arm_group_label>Dolutegravir</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada Pill</intervention_name>
    <description>Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
    <arm_group_label>Truvada</arm_group_label>
    <other_name>Tenofovir/Emtricitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy volunteer between the ages of 18 and 70, inclusive on the date of screening,
             with an intact gastrointestinal tract. Healthy is defined as no clinically relevant
             abnormalities identified by a detailed medical history, full physical examination,
             including blood pressure and pulse rate measurement, and clinical laboratory tests

          -  Recent medical history in good medical standing, without evidence of fever five days
             prior to enrollment

          -  HIV-negative

          -  Able to swallow pills

          -  Has minimum hair required to provide study samples

          -  Not allergic to any component of the study drug

          -  Signed and dated informed consent indicating that they have been informed of all
             pertinent details of the trial and are willing to participate

          -  Willing and able to comply with scheduled visits, laboratory tests and trial
             procedures

          -  Willing to use at least one form of acceptable birth control throughout the duration
             of the study

          -  Negative, or receiving treatment, for syphilis at screening

          -  Hemoglobin Grade 2 or lower, with no clinically significant medical issues that would
             preclude blood sampling

        Exclusion Criteria

          -  Age outside of desired range

          -  Confirmed positive results for HIV, Hepatitis B or C at screening

          -  Subjects of all genders actively involved in the conception process, in addition to
             cisgender female subjects who are in the immediate post-partum period or breastfeeding

          -  Insufficient amount of hair or unwilling to keep hair length at least 1 centimeter
             throughout duration of study

          -  Unable or unwilling to comply with all lifestyle measures and/or visits

          -  Impaired renal function, as documented by a creatinine clearance &lt;80 mL/min with the
             Cockcroft-Gault equation

          -  Has donated blood within the past 56 days in the amount greater than 500 mL

          -  Has taken an investigational drug in the past 4 months

          -  Clinical, laboratory, or surgical abnormalities that would preclude sample collection

          -  Has a condition, which, in the opinion of the investigator, is likely to interfere
             with follow-up or ability to take the study medication appropriately

          -  Any clinically significant laboratory result Grade 2 or greater according to the
             Division of AIDS (DAIDS) Laboratory Grading Tables

          -  History of regular alcohol consumption exceeding 14 drinks (1 drink = 5 ounces (150
             mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of spirits) per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela DM Kashuba, BScPhmPharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center, UNC Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <results_first_submitted>September 13, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 22, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Hair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03218592/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc</title>
          <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
        </group>
        <group group_id="P2">
          <title>Dolutegravir</title>
          <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
        </group>
        <group group_id="P3">
          <title>Truvada</title>
          <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1: 1 Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2: Daily Doses x 28 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 3: 0 Doses Per Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Patients Per Group</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 3: 1 Dose Per Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Patients Per Group</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 3: 3 Doses Per Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Patients Per Group</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy volunteer adults across all racial, gender and ethnicity spectrums were enrolled. Pregnant or lactating women were excluded.</population>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc</title>
          <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
        </group>
        <group group_id="B2">
          <title>Dolutegravir</title>
          <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
        </group>
        <group group_id="B3">
          <title>Truvada</title>
          <description>12 healthy volunteers will dose with Truvada (TFV/FTC) Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly. Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="22.25" upper_limit="45"/>
                    <measurement group_id="B2" value="42" lower_limit="30.5" upper_limit="51.5"/>
                    <measurement group_id="B3" value="26.5" lower_limit="23.75" upper_limit="41.75"/>
                    <measurement group_id="B4" value="32" lower_limit="24.75" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Healthy Volunteer Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hair Antiretroviral Imaging</title>
        <description>Signal Strength concentrations will be measured in hair for all study drugs, inclusive of FTC (emtricitabine), tenofovir (TFV), maraviroc (MRV), and dolutegravir (DTG) using Matrix-assisted Laser Desorption Electrospray Ionization (IR-MALDESI) to be reported by signal abundance (au). Signal abundance is the industry standard unit, and higher values represent greater signal with capability to relate to comparative concentrations.</description>
        <time_frame>Up to 28 days post dose</time_frame>
        <population>In Phase 3, the 12 participants were divided into 3 dosing categories: either zero further doses,1 dose per week, or 3 doses per week. For the single dose Phase 1, signal abundance was not able to be observed consistently for all drug arms</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O2">
            <title>Dolutegravir</title>
            <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O3">
            <title>Truvada</title>
            <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly. Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Hair Antiretroviral Imaging</title>
          <description>Signal Strength concentrations will be measured in hair for all study drugs, inclusive of FTC (emtricitabine), tenofovir (TFV), maraviroc (MRV), and dolutegravir (DTG) using Matrix-assisted Laser Desorption Electrospray Ionization (IR-MALDESI) to be reported by signal abundance (au). Signal abundance is the industry standard unit, and higher values represent greater signal with capability to relate to comparative concentrations.</description>
          <population>In Phase 3, the 12 participants were divided into 3 dosing categories: either zero further doses,1 dose per week, or 3 doses per week. For the single dose Phase 1, signal abundance was not able to be observed consistently for all drug arms</population>
          <units>Signal Abundance (au)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 3: Zero Doses Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.4826656" lower_limit="112.6510968" upper_limit="180.8064285"/>
                    <measurement group_id="O2" value="1092.130868" lower_limit="688.7225983" upper_limit="1325.75008"/>
                    <measurement group_id="O3" value="0.501209" lower_limit="0.2506045" upper_limit="11.540693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 1 Dose Per week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3942.692396" lower_limit="1054.128706" upper_limit="7097.7465"/>
                    <measurement group_id="O2" value="2377.868226" lower_limit="1241.605663" upper_limit="3519.225695"/>
                    <measurement group_id="O3" value="156.1127125" lower_limit="123.2479595" upper_limit="177.8878063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 3 Doses Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27814.98823" lower_limit="7059.467332" upper_limit="47573.27029"/>
                    <measurement group_id="O2" value="5504.883169" lower_limit="3993.758552" upper_limit="6547.002816"/>
                    <measurement group_id="O3" value="466.7986895" lower_limit="416.4048878" upper_limit="517.1924913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2: Daily Dosing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46013.29104" lower_limit="14567.14721" upper_limit="62292.81721"/>
                    <measurement group_id="O2" value="14251.46653" lower_limit="7003.462543" upper_limit="18357.12725"/>
                    <measurement group_id="O3" value="824.721385" lower_limit="593.842582" upper_limit="1378.448229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1: Single Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0" upper_limit="0">For the single dose Phase 1, signal abundance was not able to be observed consistently for all drug arms</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">For the single dose Phase 1, signal abundance was not able to be observed consistently for all drug arms</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="0" upper_limit="0">For the single dose Phase 1, signal abundance was not able to be observed consistently for all drug arms</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Blood Mononuclear Cells (PBMC) Antiretroviral Concentrations</title>
        <description>Concentrations of emtricitabine-triphosphate, tenofovir-diphosphate will be measured in peripheral blood mononuclear cells in the Truvada arm only. Truvada is a combination pill, so results for both FTC and TFV are reported in separate columns.</description>
        <time_frame>Up to 28 days post-dose</time_frame>
        <population>PBMC Concentrations were analyzed in the Truvada arm only. Results are for emtricitabine-triphosphate.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O2">
            <title>Dolutegravir</title>
            <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O3">
            <title>Tenfovir (Truvada)</title>
            <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O4">
            <title>Emtricitabine (Truvada)</title>
            <description>2nd Component in the combo pill Truvada</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood Mononuclear Cells (PBMC) Antiretroviral Concentrations</title>
          <description>Concentrations of emtricitabine-triphosphate, tenofovir-diphosphate will be measured in peripheral blood mononuclear cells in the Truvada arm only. Truvada is a combination pill, so results for both FTC and TFV are reported in separate columns.</description>
          <population>PBMC Concentrations were analyzed in the Truvada arm only. Results are for emtricitabine-triphosphate.</population>
          <units>fmol/10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 Single Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.1" lower_limit="1.2" upper_limit="18.5"/>
                    <measurement group_id="O4" value="27.09" lower_limit="1.74" upper_limit="465.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2: 7 Doses per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="127.1" lower_limit="101" upper_limit="185"/>
                    <measurement group_id="O4" value="4460" lower_limit="3620" upper_limit="5930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 3 Doses Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="60" lower_limit="54.6" upper_limit="71.8"/>
                    <measurement group_id="O4" value="2388.69" lower_limit="1341.4" upper_limit="3071.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 1 Dose Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="15.7" lower_limit="12.2" upper_limit="24.2"/>
                    <measurement group_id="O4" value="267.82" lower_limit="194.49" upper_limit="453.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: Zero Doses per week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="10.4" lower_limit="3.5" upper_limit="18.5"/>
                    <measurement group_id="O4" value="27.48" lower_limit="1.11" upper_limit="135.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Antiretroviral Concentrations</title>
        <description>Concentrations will be measured in hair of all study drugs, inclusive of FTC (emtricitabine), TFV (tenofovir), MRV (Maraviroc), and DTG (dolutegravir)</description>
        <time_frame>Up to 28 days post-dose</time_frame>
        <population>3 drug arms, but Truvada is inclusive of both TFV-dp and FTC-tp</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O2">
            <title>Dolutegravir</title>
            <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O3">
            <title>Tenofovir</title>
            <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O4">
            <title>Emtricitabine</title>
            <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Antiretroviral Concentrations</title>
          <description>Concentrations will be measured in hair of all study drugs, inclusive of FTC (emtricitabine), TFV (tenofovir), MRV (Maraviroc), and DTG (dolutegravir)</description>
          <population>3 drug arms, but Truvada is inclusive of both TFV-dp and FTC-tp</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1: Single dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3.455"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.5" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase2: 7 Doses per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.715" lower_limit="7.765" upper_limit="12.575"/>
                    <measurement group_id="O2" value="1240" lower_limit="797" upper_limit="1555"/>
                    <measurement group_id="O3" value="61.9" lower_limit="51.1" upper_limit="72.9"/>
                    <measurement group_id="O4" value="72.3" lower_limit="60.3" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 3 Doses Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.18775" upper_limit="3.955"/>
                    <measurement group_id="O2" value="69.3" lower_limit="31.4" upper_limit="155"/>
                    <measurement group_id="O3" value="9.4" lower_limit="6.6" upper_limit="45.3"/>
                    <measurement group_id="O4" value="17.2" lower_limit="8.8" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 1 Dose Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="3.095" lower_limit="1.4175" upper_limit="5.875"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.9" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 0 Doses per week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1.2725"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.5" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Whole Blood Antiretroviral Concentrations</title>
        <description>Concentrations will be measured in dried blood spots of all study drugs, inclusive of FTC (emtricitabine), TFV (tenofovir), MRV (Maraviroc), and DTG (dolutegravir). Truvada is a combination pill, so results for both FTC and TFV are reported in separate columns.</description>
        <time_frame>Up to 28 days post-dose</time_frame>
        <population>3 drug arms, but Truvada is inclusive of both TFV/FTC so reported here separately</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O2">
            <title>Dolutegravir</title>
            <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O3">
            <title>Tenofovir</title>
            <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
          <group group_id="O4">
            <title>Emtricitabine</title>
            <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly. Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Blood Antiretroviral Concentrations</title>
          <description>Concentrations will be measured in dried blood spots of all study drugs, inclusive of FTC (emtricitabine), TFV (tenofovir), MRV (Maraviroc), and DTG (dolutegravir). Truvada is a combination pill, so results for both FTC and TFV are reported in separate columns.</description>
          <population>3 drug arms, but Truvada is inclusive of both TFV/FTC so reported here separately</population>
          <units>fmol / 3mm punch</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1: Single Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="3"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="50" lower_limit="50" upper_limit="50"/>
                    <measurement group_id="O4" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2: 7 Doses per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.185" lower_limit="7.76" upper_limit="11.625"/>
                    <measurement group_id="O2" value="718.5" lower_limit="482.5" upper_limit="937.75"/>
                    <measurement group_id="O3" value="809.5" lower_limit="504.8" upper_limit="1107.5"/>
                    <measurement group_id="O4" value="280" lower_limit="214.2" upper_limit="345.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 3 Doses Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="4.2025"/>
                    <measurement group_id="O2" value="60.95" lower_limit="39" upper_limit="166.75"/>
                    <measurement group_id="O3" value="811" lower_limit="698" upper_limit="1027.5"/>
                    <measurement group_id="O4" value="150.5" lower_limit="50" upper_limit="221.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 1 Dose Per Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="3"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="644.5" lower_limit="598.2" upper_limit="1007.5"/>
                    <measurement group_id="O4" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 3: 0 Doses per week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="3"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="12.5"/>
                    <measurement group_id="O3" value="621" lower_limit="433.5" upper_limit="906"/>
                    <measurement group_id="O4" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>98 days across the individual study period</time_frame>
      <desc>We have not broken down the AE data per Phase or dosing cohort since there were none to report across any of those groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc</title>
          <description>12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
Maraviroc Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Adverse Events (AEs) reported for participants across all dose groups as there were none to report.</description>
        </group>
        <group group_id="E2">
          <title>Dolutegravir</title>
          <description>12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
Dolutegravir Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
AEs reported for participants across all dose groups as there were none to report.</description>
        </group>
        <group group_id="E3">
          <title>Truvada</title>
          <description>12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
Truvada Pill: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
AEs reported for participants across all dose groups as there were none to report.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Kashuba</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>9199969998</phone>
      <email>akashuba@unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

